Routine use of CANTAB system for detection of neuropsychological deficits in patients with PKU

Molecular Genetics and Metabolism

Volumn 102, Issue 2, 2011, Pages 210-213

  Bik Multanowski Miroslaw, M ^a   Pietrzyk, Jacek J ^a   Mozrzymas, Renata ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b Voivodeship Hospital   (Poland)

Author keywords

Computerized test; Executive function; Phenylketonuria; Prefrontal cortex; Working memory

Indexed keywords

PHENYLALANINE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION; AUTOMATION; CAMBRIDGE NEUROPSYCHOLOGICAL TEST AUTOMATED BATTERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; FEMALE; HUMAN; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; PHENYLKETONURIA; PRIORITY JOURNAL; RESPONSE TIME; WORKING MEMORY;

ADOLESCENT; ADULT; FEMALE; HUMANS; MALE; NERVOUS SYSTEM DISEASES; NEUROPSYCHOLOGICAL TESTS; PHENYLALANINE; PHENYLKETONURIAS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78651458663     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.10.003     Document Type: Article

References (12)

1. Scriver C.R., Kaufman S., Eisensmith R.C., Woo S.L.C. The hyperphenylalaninemias. The Metabolic and Molecular Bases of Inherited Disease 1995, 1015-1075. McGraw-Hill, New York. 7th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Walter J.H., White F.J., Hall S.K., MacDonald A., Rylance G., Boneh A., Francis D.E., Shortland G.J., Schmidt M., Vail A. How practical are recommendations for dietary control in phenylketonuria?. Lancet 2002, 360:55-57.
3. Smith I., Beasley M.G., Ades A.E. Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria. Arch. Dis. Child. 1990, 65:311-316.
4. Stemerdink N.B.A., van der Molen M.W., Kalverboer H.F. Prefrontal dysfunction in early and continuously treated phenylketonuria. Dev. Neuropsychopharmacolog. 2000, 16:29-57.
5. Feldmann R., Denecke J., Pietsch M., Grenzebach M., Weglage J. Phenylketonuria. No specific frontal lobe-dependent neuropsychological deficits of early-treated patients in comparison with diabetics. Pediatr. Res. 2002, 51:761-765.
6. White D.A., Nortz M.J., Mandernach T., Huntington K., Steiner R.D. Deficits in memory strategy use related to prefrontal dysfunction during early development: evidence from children with phenylketonuria. Neuropsychologia 2001, 15:221-229.
7. Huijbregts S.C., de Sonneville L.M., Licht R., van Spronsen F.J., Verkerk P.H., Sergeant J.A. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia 2004, 40:7-15.
8. Diamond A. Phenylalanine levels of 6-10mg/dl May not be as benign as once thought. Acta Paediatr. 1994, 407:S89-S91.
9. Bik-Multanowski M., Mozrzymas R., Nowacka M., Borawska-Kowalczyk U., Lange A., Starostecka E., Didycz B., Kaluzny L., Gizewska M., Szynaka E., Szymczakiewicz-Multanowska A. Use of handheld computers for assessment of prefrontal cortex function in patients with phenylketonuria. Mol. Genet. Metab. 2005, 86(Suppl. 1):S142-S144. Polish PKU Working Group.
10. de Sonneville L.M., Huijbregts S.C., van Spronsen F.J., Verkerk P.H., Sergeant J.A., Licht R. Event-related potential correlates of selective processing in early- and continuously-treated children with phenylketonuria: effects of concurrent phenylalanine level and dietary control. Mol. Genet. Metab. 2010, 99(Suppl 1):S10-S17.
11. Christ S.E., Huijbregts S.C., de Sonneville L.M., White D.A. Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol. Genet. Metab. 2010, 99(Suppl 1):S22-S32.
12. Griffiths P., Tarrini M., Robinson P. Executive function and psychosocial adjustment in children with early treated phenylketonuria: correlation with historical and concurrent phenylalanine levels. J. Intellect. Disabil. Res. 1997, 41:317-323.